Name | Title | Contact Details |
---|---|---|
Bryan Brink |
Vice President of Finance | Profile |
Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases – and underserved by current treatment options. The Company is based in Boston, and is led by partners from the biotech incubator Viridian LLC in collaboration with team at biotech accelerator Xontogeny LLC, and with funding from the Perceptive Xontogeny Venture Fund. The Quellis team has deep experience in mAb discovery and development, company creation, and private and public biotech investment. Our shared goal is to create meaningful medicines for every disease we target.
MYM Nutraceuticals Inc. (CSC:MYM) (OTC:MYMMF) (FRA:OMY) is an emerging bio-pharmaceutical company and distributor of medical marijuana products that has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations. MYM Nutraceuticals has an extensive list of industry assets that make it well prepared for commercial distribution of medical marijuana, including a growing facility property, exclusive access to patients and many years of industry expertise on the company`s board of directors and staff.
ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases with significant unmet medical need.
Quench Bio is a biotechnology company leveraging new insights into gasdermin biology and innate immunity to develop medicines for severe inflammatory diseases.
Bioscience, Inc. is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.